Compare AbCellera Biologics Inc (ABCL) vs Ecopetrol SA (EC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Ecopetrol SA — how do they compare? AbCellera Biologics Inc trades at $7.19 (market cap $2.35B), while Ecopetrol SA trades at $15 (market cap $28.19B). The key difference: Ecopetrol SA is far larger — about 12× AbCellera Biologics Inc's market cap, and Ecopetrol SA pays a 4.42% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | EC | |
|---|---|---|
Market Cap | $2.35B | $28.19B |
Sector | Health | Energy |
52-Week High | $8.12 | $16.58 |
52-Week Low | $2.78 | $8.29 |
Enterprise Value | $1.99B | $55.97B |
Dividend Yield | — | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Ecopetrol (EC) trades at $14.69, slightly below the consensus price target of $14.63, with a bearish technical signal and mixed earnings performance. Recent quarters show misses against EPS expectations, while revenue has declined from $159.6T in 2022 to $119.7T in 2025. The company maintains a dividend payout, with a recent H1-26 dividend of $0.66, and holds a BB- credit rating with a stable outlook as affirmed by S&P Global Ratings on June 17, 2026.
The outlook remains cautious due to declining revenue and profitability trends, offset by attractive valuation multiples like a P/E of 10.31. Key risks include operational execution in the energy sector and macroeconomic pressures on oil demand. Analyst sentiment is mixed with a Hold-dominated consensus, suggesting limited near-term upside potential amid ongoing fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
